Dr. Jeroen Aerssens serves as Chief Development Officer at Rejuvenate Biomed. In this role, he leads the company’s clinical research and development activities including compound development strategy, clinical trial design and execution, clinical translational science and collaborations with stakeholders. With over 25 years of experience in the pharmaceutical industry (Johnson & Johnson companies), Jeroen brings deep scientific and operational expertise in clinical translational science, biomarker development, and drug discovery. He has held multiple senior scientific leadership positions spanning preclinical research, translational medicine, and clinical development. Jeroen actively contributed to advance clinical development programs of candidate drugs across various therapeutic areas, including market-approved drugs such as galantamine (Alzheimer’s disease), telaprevir and simeprevir (hepatitis C). His scientific deliverables are reflected in more than 130 co-authored peer-reviewed publications and over 20 co-invented patent applications, covering diverse fields such as infectious diseases, bone disorders, metabolic syndrome, gastroenterology, neuroscience, and oncology. Jeroen holds a PhD in Medical Sciences, a master’s degree in Bioengineering, and a postgraduate certificate in Health Economics.